Marek Babjuk

How did these international partnerships help translate promising science into therapies that can reach patients globally?

Crucial, of course, another collaboration to emphasize Professor Marek Babjuk in Prague, who is a leader in the field of bladder cancer internationally.

His team have been responsible for the earlier studies, and they are now working with us on the phase three.

There is a lot of expertise and experience with the drug in that team, and we hope that that is going to make it a smoother and faster study to really understand the extent to which alpha-1H is affecting the tumors.